Cancer Immunology
Understanding the complex interplay between the immune system and cancer cells to identify therapeutic vulnerabilities and design immune-based interventions.
Advancing the future of cancer immunotherapy.
Translating fundamental discoveries in immunology into innovative therapies that improve outcomes for patients with cancer — through translational research, biomarker discovery, precision oncology, and scientific leadership.
0+
Years in cancer immunology & translational oncology
0
Peer-reviewed publications in leading journals
0
Scientific books edited, plus four authored chapters
0
Patents in cancer immunotherapy
About
A scientific life devoted to translational impact.
I am a translational cancer immunologist with more than 15 years of experience dedicated to understanding how the immune system can be harnessed to develop innovative therapies for cancer. My career has been driven by a single mission: to translate fundamental discoveries in immunology into transformative therapies that improve outcomes for patients.
I previously served as an Assistant Professor at The University of Texas MD Anderson Cancer Center, where I led independent and collaborative research programs focused on cancer immunotherapy, tumor microenvironment biology, inflammation, biomarker discovery, and translational drug development.
Throughout my career, I have collaborated with leading academic investigators, clinicians, and pharmaceutical partners, including 3M and Memgen, LLC, to translate scientific discoveries into therapies with clinical potential. My research has contributed to translational programs, informed clinical trial strategies, and resulted in two patents in the field of cancer immunotherapy.
Vision
Integrate immunology, biomarker science, spatial transcriptomics, and precision medicine to develop safer, more effective, and personalized cancer immunotherapies.
Research Program
Rational immunology.
Translational impact.
My research is centered on identifying novel therapeutic targets and developing next-generation cancer immunotherapies, with a focus on enhancing efficacy and durability through rational combination approaches that overcome resistance while minimizing toxicity.
01
Rational Combination Immunotherapy
Enhancing the efficacy and durability of anti-cancer immunotherapies through combination strategies that overcome resistance while minimizing toxicity.
02
Immune Signaling & Inflammation
Interrogating IL-1 signaling, CD40 agonists, TLR7/8 agonists, and immune checkpoint pathways to unlock new therapeutic modalities.
03
Tumor Microenvironment Biology
Decoding the cellular and molecular architecture of tumors using spatial transcriptomics and single-cell technologies.
04
Biomarker-Guided Precision Oncology
Developing immune profiling and translational biomarkers to stratify patients and predict therapeutic response.
Areas of Expertise
A cross-disciplinary translational toolkit.
Cancer Immunotherapy
Developing and optimizing immune-based treatments including checkpoint inhibitors, adoptive cell therapies, cancer vaccines, and rational combination approaches.
Translational Oncology
Bridging laboratory discoveries to clinical application through rigorous preclinical validation, biomarker-informed trial design, and regulatory strategy.
Drug Discovery & Development
Leading target identification, lead optimization, mechanism-of-action studies, and preclinical characterization of novel therapeutic candidates.
Tumor Microenvironment
Decoding the cellular and molecular architecture of tumors to identify immunosuppressive mechanisms and uncover new therapeutic entry points.
Biomarker Discovery
Developing predictive and prognostic biomarkers to stratify patients, monitor therapeutic response, and guide precision treatment decisions.
Precision Oncology
Tailoring cancer treatments to individual patients based on molecular profiling, immune landscape characterization, and real-world evidence.
IL-1 Biology & Inflammation
Investigating IL-1 family cytokines as key modulators of tumor immunity and as therapeutic targets for rational combination strategies.
B-cell Immunology
Exploring the multifaceted roles of B cells, tertiary lymphoid structures, and humoral immunity in shaping anti-tumor immune responses.
Antigen Presentation & NLRC5
Studying MHC-I antigen presentation machinery and NLRC5 regulation as critical mechanisms of immune evasion and therapeutic vulnerability.
Spatial Transcriptomics
Leveraging spatially resolved gene expression technologies to map tumor heterogeneity, immune infiltration patterns, and cell-cell interactions.
Single-Cell Genomics
Applying single-cell RNA and multi-omics approaches to dissect cellular diversity, lineage dynamics, and microenvironmental states in tumors.
Immuno-Oncology
Designing rational combination strategies to enhance the efficacy, durability, and breadth of cancer immunotherapies across tumor types.
Scientific Leadership
Building and mentoring high-performing research teams while driving strategic scientific direction across multidisciplinary programs.
Cross-Functional Collaboration
Fostering partnerships across academia, biotechnology, pharmaceutical industry, and clinical medicine to accelerate translational impact.
Grant Strategy & Scientific Review
Securing competitive federal and foundation funding while evaluating research proposals for scientific merit and translational potential.
Selected Publications
Peer-reviewed contributions.
- 01Rational combination strategies to overcome resistance in cancer immunotherapy — Frontiers in Immunology.
- 02IL-1 signaling as a therapeutic axis in the tumor microenvironment — peer-reviewed review.
- 03NLRC5 and MHC-I antigen presentation in tumor immune evasion — mechanistic study.
- 04CD40 agonists and TLR7/8 activation in reprogramming the tumor immune landscape.
- 05Biomarker-guided approaches to immune checkpoint blockade response prediction.
- 06B-cell immunology in solid tumors: translational perspectives.
Representative of 40 peer-reviewed publications across leading scientific journals.
Books & Book Chapters
Editor, author, and contributor to the scientific record.
Books Edited
- Advances in Cancer Immunology — Editor
- Translational Cancer Immunotherapy — Editor
- Tumor Microenvironment & Therapeutic Targets — Editor
- Precision Oncology: Biomarkers & Beyond — Editor
Book Chapters
- Combination Immunotherapy Strategies in Solid Tumors
- IL-1 Family Cytokines in Cancer Biology
- Antigen Presentation Machinery as a Therapeutic Vulnerability
- Biomarker Discovery for Immune Checkpoint Blockade
In Progress / Forthcoming
- Emerging Frontiers in Cancer Immunotherapy — In progress
- The Tumor Microenvironment: A Translational Atlas — In progress
- God Exists — Forthcoming — science & spirituality
- When Science Meets Spirituality — Forthcoming
Grants · Patents · Funding
Sustained investment in translational science.
Grant
Federal Research Funding
Successfully secured and contributed to competitive research funding supporting translational cancer immunology programs.
Grant
Institutional & Foundation Awards
Recipient of institutional and foundation-level awards advancing biomarker discovery and combination immunotherapy research.
Grant
Industry-Sponsored Research
Led and co-led sponsored research programs with biotechnology and pharmaceutical partners including 3M and Memgen, LLC.
Patent
Novel Immunotherapeutic Composition & Method
Cancer immunotherapy — combination approach targeting the tumor immune landscape.
Patent
Biomarker-Guided Therapeutic Strategy
Precision oncology — predictive biomarker platform for immunotherapy response.
Industry Collaborations
Academic rigor meets industry translation.
- 3M — industry translational collaboration
- Memgen, LLC — immunotherapy development
- The University of Texas MD Anderson Cancer Center
- Academic clinicians & translational investigators
- Biotechnology & pharmaceutical R&D partners
- Grant review panels & scientific advisory boards
Scientific Leadership
Building programs, mentoring people, shaping the field.
Faculty Leadership
Formerly Assistant Professor at The University of Texas MD Anderson Cancer Center, leading independent and collaborative research programs in cancer immunotherapy.
Editorial & Peer Review
Active contributor to scientific publishing through peer review, editorial activities, grant review, and book editing across cancer immunology.
Scientific Community
Ongoing engagement with grant review panels, multidisciplinary collaborations, and knowledge dissemination to trainees and clinicians.
Speaking Engagements — Available for keynote lectures, invited seminars, conference presentations, workshops, and educational programs on cancer immunology, translational oncology, biomarkers, immunotherapy, and precision medicine.
Advisory & Consulting
Working with organizations advancing cancer therapies.
- 01
Scientific Advisory
Advisory roles for biotech, pharma, academic institutions, investors, and nonprofits developing oncology and immunology therapies.
- 02
Scientific Consulting
Strategic guidance across cancer immunotherapy, translational drug development, tumor microenvironment biology, and precision oncology.
- 03
Grant Review & Strategy
NIH, DoD, CPRIT, foundation, and industry-sponsored panel review; proposal development and translational funding strategy.
- 04
Grant Writing
Proposal development, research strategy, and multidisciplinary program design for competitive federal and foundation funding.
- 05
Scientific & Medical Writing
Manuscripts, review articles, white papers, technical reports, and grant applications for academic and industry audiences.
- 06
Journal Editorial & Peer Review
Editorial board appointments, paid scientific editing, manuscript evaluation, and peer review for biomedical publishers.
- 07
Due Diligence
Scientific evaluation of emerging immunotherapy technologies, therapeutic targets, biomarkers, and preclinical programs.
- 08
Speaking Engagements
Keynote lectures, invited seminars, conference presentations, workshops, and educational programs worldwide.
Mentoring
Investing in the next generation of scientists.
Mentoring is central to my scientific practice. I work with trainees and early-career investigators on research strategy, grant writing, scientific communication, and career development — helping them navigate transitions into independent research and industry.
- Graduate students & postdoctoral fellows
- Early-career investigators
- Scientists transitioning to independent research
- Industry-track career mentoring
Science · Consciousness · Scholarly Writing
Where scientific inquiry meets the search for meaning.
Alongside my career as a cancer immunologist, I explore the intersection of science, consciousness, and spirituality through scholarly writing. My forthcoming books, God Exists and When Science Meets Spirituality, reflect an ongoing intellectual curiosity that has always accompanied my scientific work — the belief that open-minded inquiry across disciplines fosters creativity, innovation, and a broader understanding of life.
News & Research Updates
Latest from the research program.
Publication
New review on rational combination immunotherapy strategies
Highlighting translational approaches to overcome resistance in solid tumors.
Read moreSpeaking
Invited lecture on IL-1 biology in the tumor microenvironment
Discussing therapeutic modulation of inflammation in cancer immunotherapy.
Read moreBook
Forthcoming: Emerging Frontiers in Cancer Immunotherapy
New volume synthesizing recent advances across immuno-oncology and precision medicine.
Read moreCurriculum Vitae
Full academic and professional record.
Publications, patents, grants, collaborations, leadership, editorial service, and invited presentations.
FAQ
Frequently asked questions.
Yes. I currently accept scientific advisory roles with biotechnology, pharmaceutical, and nonprofit organizations focused on oncology and immunology.
Contact
Let's advance the science together.
For advisory, consulting, faculty, industry leadership, speaking, editorial, or collaborative research inquiries — please reach out directly.